Pharma Mar S.A.(PHM)

Description: Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

---

Keywords: Biopharmaceutical Solid Tumors Prostate Cancer Orphan Drug Antineoplastic Drugs Ovarian Cancer Macular Degeneration Small Cell Lung Cancer Gene Expression Sarcoma Soft Tissue Sarcoma Retinitis Pigmentosa Evofosfamide Trabectedin Yondelis Ocular Allergies Aplidin R/R Multiple Myeloma Ecubectedin (Pm14) Patrick Schöffski Pm534 Pm54 Syl116011 Syl1801 Treatment Of Soft Tissue Sarcoma And Prostate Cancer

---

Home Page: www.pharmamar.com

Avenida de los Reyes, 1
Madrid, 28770
Spain
Phone: 34 91 846 60 00

---

Officers

Exchange: MC

Country: ES : Spain

Currency: Euro (€)